Overview

A Safety and Dose-Determining Study of CMX001 In Infants With Neonatal Herpes Simplex Virus (HSV) Infection Involving the Central Nervous System (CNS Disease)

Status:
Withdrawn

Trial end date:
2017-06-01

Target enrollment:

Participant gender:

Summary

This study is to identify if a Novel Antiviral Drug could be used to treat babies with Herpes Simplex Virus (HSV) with central nervous system (CNS) disease. In this study the investigators will identify the best dose for young children as well as identify additional safety information about the Novel Antiviral Drug.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of Alabama at Birmingham

Treatments:

Acyclovir
Antiviral Agents